New tools and capabilities in the Analyzera MCP connector, newest first. Everything here works in any assistant you have connected; nothing needs reinstalling.
See how a portfolio's current holdings would have fared in 19 named market episodes since 2007, from the financial crisis and Covid to the 2022 rate rises. Ask your assistant, or browse them in the dashboard.
Run every episode, worst first, or pick them by theme: equity crashes, rising or falling rates, inflation, currency shocks and recoveries.
The full detail adds each episode's story, its main drivers and the currency effect.
Replay a benchmark or another portfolio the same way to compare them.
A replay of today's holdings through past market moves, not a forecast, and not what the portfolio held at the time.
Try“How would my portfolio have held up in the 2008 financial crisis and the 2022 rate rises?”
Create a read-only link to a strategy's dashboard for WhatsApp, SMS, mail or Slack. Viewers see every tab and can copy the strategy into their own Analyzera account.
A shared page shows live figures as weights and percentages only, never values, amounts or units.
Every tab is shared and copying is on by default; ask for a single tab, or no copying, when you make the link.
A copy belongs to the viewer. Nobody with the link can change your account.
List your live links at any time, and revoke one to turn it off.
Try“Share my Nordic dividend strategy as a link a colleague can copy.”
Build an equity strategy weighted by market cap or equally, and keep it inside the same caps as every other construction method, such as a maximum weight per stock.
Choose market-cap, equal, minimum-risk or risk-parity weighting when you build an equity strategy. The caps apply to all four.
The per-stock cap is 10% by default, and you can set your own.
Where no cap binds, the weights stay exactly market-cap or equal; a cap only changes what it has to.
If a cap cannot be met, for example too few stocks for a tight cap, the result says what was relaxed.
Try“Build an equal-weighted strategy of European healthcare stocks, with no stock above 5%.”